Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

28.31 +1.24 (+4.58%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Energizer, C3.ai, Insmed And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Lululemon To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday
 
Via Benzinga
Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday
Sales of the company's top commercialized product didn't meet expectations. 
Via The Motley Fool
Apellis Pharmaceuticals Dives On Worse-Than-Expected Syfovre Sales
The company is best known for its drug, Syfovre, a treatment for geographic atrophy. 
Via Investor's Business Daily
Celanese Posts Downbeat Results, Joins Cirrus Logic, Teradata And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
 
Via Benzinga
A Glimpse of Apellis Pharmaceuticals's Earnings Potential
 
Via Benzinga
The Latest Analyst Ratings For Apellis Pharmaceuticals
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst
It has been a rotten year for Apellis Pharmaceuticals stock, but better times could be ahead. 
Via The Motley Fool
Navigating 18 Analyst Ratings For Apellis Pharmaceuticals
 
Via Benzinga
Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch
William Blair initiates coverage of Apellis Pharmaceuticals, highlighting its innovative therapies for complement C3 targeting. The analyst forecasts significant growth opportunities with peak sales... 
Via Benzinga
CrowdStrike To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Monday
 
Via Benzinga
Analyst Scoreboard: 15 Ratings For Apellis Pharmaceuticals
 
Via Benzinga
Critical Insights From Apellis Pharmaceuticals Analyst Ratings: What You Need To Know
 
Via Benzinga
Peeling Back The Layers: Exploring Apellis Pharmaceuticals Through Analyst Insights
 
Via Benzinga
What's Going With Apellis Pharmaceuticals Stock Friday?
Apellis Pharmaceuticals shares are moving lower after the Committee for Medicinal Products for Human Use of the European Medicines Agency confirmed its June 2024 negative opinion following... 
Via Benzinga
Apellis Stock Hammered After Eye Drug Gets A Third European Rejection
The company is "out of European approval options" for its embattled geographic atrophy drug, says one analyst. 
Via Investor's Business Daily
Wedbush Just Raised its Price Target on These 7 Stocks: August 12, 2024
New Wedbush price targets have been issued for each of the following seven stocks, including a few that may come as a surprise to some. 
Via InvestorPlace
Apellis Pharmaceuticals' Pegcetacoplan Meets Primary Goal In Late-Stage Study In Patients With Rare Kidney Diseases
Swedish Orphan Biovitrum and Apellis Pharmaceuticals released topline results from the Phase 3 VALIANT study of pegcetacoplan for C3 glomerulopathy and IC-MPGN. The study met primary and secondary... 
Via Benzinga
What Analysts Are Saying About Apellis Pharmaceuticals Stock
 
Via Benzinga
Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 15 Analysts
 
Via Benzinga
In-Depth Examination Of 14 Analyst Recommendations For Apellis Pharmaceuticals
 
Via Benzinga
Expert Ratings For Apellis Pharmaceuticals
 
Via Benzinga
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,000 Today
 
Via Benzinga
Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session
 
Via Benzinga
APLS Stock Earnings: Apellis Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024
APLS stock results show that Apellis Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
$1000 Invested In This Stock 5 Years Ago Would Be Worth $3,000 Today
 
Via Benzinga
Decoding 15 Analyst Evaluations For Apellis Pharmaceuticals
 
Via Benzinga
Peering Into Apellis Pharmaceuticals's Recent Short Interest
 
Via Benzinga
Deep Dive Into Apellis Pharmaceuticals Stock: Analyst Perspectives (18 Ratings)
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.